Actively Recruiting
Esomeprazole and Radiation Induced Esophagitis
Led by Rush University Medical Center · Updated on 2025-04-13
48
Participants Needed
1
Research Sites
226 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Thoracic radiation therapy combined with chemotherapy (with or without immunotherapy) is the cornerstone of management in patients with locally advanced non-small cell lung cancer (NSCLC).
CONDITIONS
Official Title
Esomeprazole and Radiation Induced Esophagitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient is 18 years of age or older.
- Patient or patient's legal representative can provide written informed consent and HIPAA authorization before any study activities.
- Patient is willing and able to attend scheduled visits and follow treatment plans.
- Patient has confirmed NSCLC clinical stage III diagnosis according to the 8th edition AJCC staging.
- Patient will receive thoracic radiation therapy with estimated esophageal dose of at least 30 Gy (EQD2) alongside chemotherapy.
- Patient has an ECOG performance status score between 0 and 2.
- Women who can become pregnant must have a negative pregnancy test within 2 weeks before enrollment.
- Participation in another trial is allowed if the other trial permits dual enrollment.
You will not qualify if you...
- History of gastroesophageal junction or stomach cancer.
- History of severe or very severe swallowing difficulties (dysphagia).
- History of severe liver disease or acute/subacute systemic lupus erythematosus.
- Diagnosis of interstitial nephritis.
- History of peptic ulcer disease.
- Previous upper gastrointestinal bleeding.
- Thoracic radiation therapy within 2 years before enrollment.
- Known or suspected allergy or adverse reaction to proton pump inhibitors.
- Current use of clopidogrel, nelfinavir, rilpivirine, methotrexate, rifampin, digoxin, tacrolimus, or phenytoin.
- Not receiving concurrent chemoradiotherapy or esophageal radiation dose below 30 Gy (EQD2).
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rush University Medical Center
Chicago, Illinois, United States, 60612
Actively Recruiting
Research Team
S
Soumyajit Roy, MD, MSc.(c)
CONTACT
G
Gaurav Marwaha, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here